慢性心力衰竭患者经沙库巴曲缬沙坦钠联合呋塞米、去乙酰毛花苷治疗的疗效及心功能分析

Analysis of curative effect and cardiac function of patients with chronic heart failure treated with sakobactri valsartan sodium combined with furosemide and deacetylacanthine

目的:探讨沙库巴曲缬沙坦钠联合呋塞米、去乙酰毛花苷治疗慢性心力衰竭(CHF)的临床疗效。方法:选取2018年1月~2019年12月我院CHF患者145例,按随机数字表法分研究组(n=73)、对照组(n=72)。均予以呋塞米、去乙酰毛花苷等常规治疗,在此基础上,对照组采用依那普利治疗,研究组采用沙库巴曲缬沙坦钠治疗。比较两组总有效率、治疗前后心功能[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、心排血量(CO)]、运动耐力[6min步行试验(6MWT)]、血浆神经内分泌因子[N末端脑钠肽前体(NT-pro BNP)、抗利尿激素(ADH)]、基质金属蛋白酶9(MMP-9)水平及治疗后6个月主要不良心血管事件(MACE)发生率。结果:研究组总有效率为94.52%(69/73),高于对照组80.56%(58/72)(P<0.05)。治疗后研究组LVEF、CO及6MWT高于对照组,LVEDD低于对照组(P<0.05)。治疗后研究组血浆NT-pro BNP、ADH、MMP-9水平均低于对照组(P<0.05)。研究组治疗后6个月MACE发生率为1.39%(1/72),低于对照组11.11%(8/72)(P<0.05)。结论:沙库巴曲缬沙坦钠联合呋塞米、去乙酰毛花苷治疗CHF的临床疗效显著,可有效提升患者心功能及运动耐力,同时抑制心室重构,改善患者预后。

Objective:To investigate the clinical efficacy of sakobactrivalsartan sodium combined with furosemide and deacetylacanthine in the treatment of chronic heart failure(CHF).Methods:A total of 145 patients with CHF in our hospital from January 2018 to December 2019 were selected and divided into study group(n=73)and control group(n=72),according to random number table method.On this basis,the control group was treated with enalapril,and the research group was treated with sakobactrum valsartan sodium.Total response rate,cardiac function before and after treatment[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),cardiac output(CO)],exercise endurance[6min walking test(6MWT)],plasma neuroendocrine factor[N-terminal brain natriuretic peptide precursor(NT-pro BNP),antidiuretic hormone(ADH)],matrix metalloproteinase 9(MMP-9)and the incidence of major adverse cardiovascular events(MACE)6 months after treatment were compared between the two groups.Results:The total effective rate of study group was 94.52%(69/73),which was higher than that of control group 80.56%(58/72)(P<0.05).After treatment,LVEF,CO and 6MWT in the study group were higher than those in the control group,while LVEDD was lower than that in the control group(P<0.05).After treatment,plasma NT-Pro BNP,ADH and MMP-9 levels in the study group were lower than those in the control group(P<0.05).The incidence of MACE 6 months after treatment in the study group was 1.39%(1/72),lower than that in the control group(11.11%(8/72))(P<0.05).Conclusion:Sakobactrivalsartan sodium combined with furosamide and deacetylacanthine has significant clinical efficacy in the treatment of CHF,which can effectively improve the cardiac function and exercise endurance of patients,inhibit ventricular remodeling,and improve the prognosis of patients.